<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878303</url>
  </required_header>
  <id_info>
    <org_study_id>AC00582017-101</org_study_id>
    <nct_id>NCT03878303</nct_id>
  </id_info>
  <brief_title>Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)</brief_title>
  <official_title>A Phase 1b Double-Blind, Randomized, Placebo-Controlled Study of the Safety, Pharmacokinetics and Pharmacodynamics of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ACEA Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hangzhou ACEA Pharmaceutical Research Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ACEA Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, double blind, randomized, placebo-controlled study of the safety and&#xD;
      tolerability, pharmacokinetics and pharmacodynamics of AC0058TA in patients with systemic&#xD;
      lupus erythematosus (SLE).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be performed in adult patients with autoantibody (ANA) positive SLE, as&#xD;
      defined by the American College of Rheumatology (ACR) 1997 criteria or System Lupus&#xD;
      International Collaborating Clinic (SLICC) 2009 criteria who are receiving standard of care&#xD;
      therapy for SLE.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events</measure>
    <time_frame>Measured up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration and Area Under the Curve</measure>
    <time_frame>Measured on Day 1, Day 28, and Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of AC0058TA: Bruton's tyrosine kinase (BTK) occupancy (% occupancy)</measure>
    <time_frame>Measured on Day 1, Day 28, and Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of AC0058TA: serum antidsDNA antibodies, ANAs, complement (C3 and C4) and B-cell markers</measure>
    <time_frame>Measured on Day 1, Day 28, and Day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>AC0058TA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AC0058TA will be administered in 25 mg capsules orally at the following doses: 50 mg QD, 100 mg QD, 200 mg QD and 100 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo AC0058TA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo AC0058TA will be administered orally at the equivalent dose of investigational product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC0058TA</intervention_name>
    <description>25 mg capsules</description>
    <arm_group_label>AC0058TA</arm_group_label>
    <other_name>AC0058</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo AC0058TA</intervention_name>
    <description>equivalent dose of investigational product</description>
    <arm_group_label>Placebo AC0058TA</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of SLE according to ACR 1997 criteria or 2009 SLE-SLICC criteria&#xD;
             with ANA positive (≥ 1:40) patients who could receive hydroxychloroquine and/or&#xD;
             steroids treatment.&#xD;
&#xD;
          2. Adequate hematopoietic function, including:&#xD;
&#xD;
               -  Platelet count &gt; 75 × 10^9/L&#xD;
&#xD;
               -  Leukocyte ≥ 2.0 × 10^9/L including CD19+ B cell counts of at least 50/μL&#xD;
&#xD;
               -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          3. Adequate liver function&#xD;
&#xD;
               -  Bilirubin: &lt; 1.2 X upper limit of normal (ULN)&#xD;
&#xD;
               -  AST: &lt; 1.2 X upper limit of normal (ULN)&#xD;
&#xD;
               -  ALT: &lt; 1.2 X upper limit of normal (ULN)&#xD;
&#xD;
          4. Adequate renal function:&#xD;
&#xD;
             a. BUN and creatinine:&lt; 1.5 X upper limit of normal (ULN)&#xD;
&#xD;
          5. Female of reproductive potential must agree to use two forms of contraception during&#xD;
             screening, during the study, and for at least 30 days after the last dose of AC0058TA.&#xD;
&#xD;
          6. Able to provide written informed consent in accordance with federal, local, and&#xD;
             institutional guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active central nervous system (CNS) lupus (including seizures, psychosis, organic&#xD;
             brain syndrome, cerebrovascular accident [CVA], cerebritis or CNS vasculitis) or&#xD;
             active bleeding disorder within 60 days prior to the first day of study treatment.&#xD;
&#xD;
          2. Clinical evidence of significant unstable or uncontrolled acute or chronic diseases&#xD;
             other than SLE which, in the opinion of the investigator, could confound the results&#xD;
             of the study, put the patient at undue risk, or interferes with protocol adherence, or&#xD;
             a subject's ability to give informed consent.&#xD;
&#xD;
          3. History or presence of congestive heart failure (New York Heart Association&#xD;
             [NYHA]Class III to IV), symptomatic ischemia, clinically significant conduction&#xD;
             abnormalities uncontrolled by conventional intervention, or myocardial infarction&#xD;
             within 6 months prior to the first day of study treatment.&#xD;
&#xD;
          4. Have severe lupus complications (Acute Lupus Pneumonitis, Diffuse Alveolar Hemorrhage,&#xD;
             Chronic Interstitial Pneumonia, Pulmonary Hypertension, Pulmonary Embolism) severe&#xD;
             lupus gastrointestinal diseases (Lupus Mesenteric Vasculitis, Protein-Losing&#xD;
             Enteropathy, Pancreatitis, Intestinal Pseudo-Obstruction).&#xD;
&#xD;
          5. History of any bleeding disorder secondary to SLE.&#xD;
&#xD;
          6. Have active, severe lupus kidney disease WHO III-V (Rapidly Progressive&#xD;
             Glomerulonephritis, Nephrotic Syndrome, Renal Tubular Acidosis, Renal Insufficiency),&#xD;
             proteinuria &gt; 500 mg/day.&#xD;
&#xD;
          7. Acute or chronic infections requiring systemic antibiotic, antifungal, or antiviral&#xD;
             therapy within 60 days of the first day of study treatment.&#xD;
&#xD;
          8. Known HIV infection or positive for hepatitis B virus infection (HBsAg positive,&#xD;
             HBeAg, HBeAb or HBcAb positive and HBV DNA positive) or hepatitis C antibody positive&#xD;
             (HCV RNA positive).&#xD;
&#xD;
          9. Primary immunodeficiency other than complement deficiencies.&#xD;
&#xD;
         10. Active or latent tuberculosis within 6 months prior to the first day of study&#xD;
             treatment.&#xD;
&#xD;
         11. Receipt of a live-attenuated vaccine within 2 months prior to screening.&#xD;
&#xD;
         12. Within 2 weeks prior to screening：Use of injectable corticosteroids.&#xD;
&#xD;
         13. Within 2 months prior to screening: use of abatacept, anti-tumor necrosis factor alpha&#xD;
             agents, intravenous immunoglobulin, plasmapheresis, mycophenolate, MTX and leflunomide&#xD;
             or therapies not otherwise specified in protocol.&#xD;
&#xD;
         14. Use of cyclophosphamide or chlorambucil within five half-lives of screening.&#xD;
&#xD;
         15. Use of rituximab, belimumab, or any other B cell-depleting or modulating therapies&#xD;
             within 6 months of screening.&#xD;
&#xD;
         16. Female patients who are pregnant or breastfeeding.&#xD;
&#xD;
         17. Use of an investigational therapeutics within 30 days or 5 half-lives prior to&#xD;
             screening, whichever is greater.&#xD;
&#xD;
         18. Has a positive pregnancy test result at Screening or Check-in (females only).&#xD;
&#xD;
         19. Women with childbearing potential are defined as all women who are physiologically&#xD;
             able to have a pregnancy, unless they are using an efficient contraceptive method&#xD;
             during treatment and within 30 days after discontinuation of treatment as below.&#xD;
&#xD;
               1. Complete abstinence (if this is in line with the subject's preferred and usual&#xD;
                  lifestyle). Periodic abstinence (e.g., calendaring method, ovulation method,&#xD;
                  symptomatic body temperature method, post-ovulation method) and in vitro&#xD;
                  ejaculation are unacceptable contraceptive methods.&#xD;
&#xD;
               2. Patients who have received female sterilization (bilateral ovariectomy with or&#xD;
                  without hysterectomy) or tubal ligation for at least 6 weeks prior to study&#xD;
                  treatment. In case of only unilateral ovariectomy, female fertility status must&#xD;
                  be confirmed by follow-up assessment of hormone levels.&#xD;
&#xD;
               3. Combination of the following two methods:&#xD;
&#xD;
                    -  Intrauterine device (IUD) or intrauterine system (IUS).&#xD;
&#xD;
                    -  Barrier contraceptive methods: condoms or cervical cap (diaphragm or&#xD;
                       cervical cap) coated with spermicidal foam/gel/cream/vaginal suppositories.&#xD;
                       If women use oral contraceptives only, they should use the same&#xD;
                       contraceptives at a stable dose for at least 3 months before starting the&#xD;
                       study treatment.&#xD;
&#xD;
               4. If women have at least 12 months of natural amenorrhea and are clinically&#xD;
                  compatible (e.g., at the corresponding age, with a history of vasomotor symptoms&#xD;
                  or received bilateral ovariectomy with or without hysterectomy, they are regarded&#xD;
                  as postmenopausal women with no childbearing potential. In case of only&#xD;
                  unilateral ovariectomy, female fertility status must be confirmed by follow-up&#xD;
                  assessment of hormone levels before the women can be considered to have no&#xD;
                  childbearing potential.&#xD;
&#xD;
         20. Men who have sexual intercourse unless they use a condom during sexual intercourse and&#xD;
             must not donate sperm from the first dose of study drug until 30 days after&#xD;
             discontinuation of treatment and do not impregnate their sexual partners during the&#xD;
             period. Vasectomized males are also required to use condoms to prevent the&#xD;
             transmission of drugs through semen.&#xD;
&#xD;
         21. Subject who, in the opinion of the Investigator, should not participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy Fleischmann, MD MACR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metroplex Clinical Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liming Liu, MD, PhD</last_name>
    <phone>1-858-249-9120</phone>
    <email>limingliu@aceatherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Fleischmann, MD MACR</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SLE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

